Naproxen

Generic Name: Naproxen

Brand Names: Aleve, Aleve PM, Aleve-D, Anaprox, Naprelan, Naprosyn, Sallus, Sudafed Sinus & Pain, Treximet, Vimovo

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₁₄O_₃

CAS Number: 22204-53-1

Unique Ingredient Identifier: 57Y76R9ATQ

Background: Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, nap...

Indication: Naproxen is indicated for the management of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, tendinitis, bursitis, acute gout, primary dysmenorrhea, and for the relief of mild to moderate pain. Further, it is first-line therapy for osteoarthritis, acute gouty arthritis, dysmenorrhea, and musculoskelet...

Associated Conditions: Acute Gouty Arthritis, Acute Migraine, Ankylosing Spondylitis (AS), Back pain, Bursitis, Extra-Articular Rheumatism, Fever, Flu caused by Influenza, Headache, Juvenile Idiopathic Arthritis (JIA), Menstrual Distress (Dysmenorrhea), Migraine, Muscle Spasms, Nasal Congestion, Osteoarthritis (OA), Pain, Post Traumatic Pain, Postoperative pain, Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Seasonal Allergic Rhinitis, Sinusitis, Tendinitis, Toothache, Articular inflammation

Associated Therapies: -

Clinical Trials

Brain Imaging To Examine The Effect Of Naproxen In Hand Osteoarthritis Patients

Early Phase 1

Completed

Conditions: Osteoarthritis

Interventions: Drug: Placebo
Drug: Naproxen

First Posted Date: 2009-01-27

Last Posted Date: 2011-03-14

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT00830050

Locations: 🇬🇧
Pfizer Investigational Site, Denmark Hill, London, United Kingdom

Tanezumab In Osteoarthritis Of The Knee (2)

Phase 3

Completed

Conditions: Osteoarthritis
Arthritis

Interventions: Biological: tanezumab 5 mg
Biological: tanezumab 10 mg
Other: placebo
Drug: naproxen

First Posted Date: 2009-01-27

Last Posted Date: 2021-05-13

Lead Sponsor: Pfizer

Target Recruit Count: 832

Registration Number: NCT00830063

Locations: 🇺🇸
Valley Research, Fresno, California, United States
🇺🇸
Holston Medical Group, Kingsport, Tennessee, United States
🇺🇸
Jeffrey D. Lieberman, MD, Decatur, Georgia, United States

and more 89 locations

Treatment Study of Steroid Injection and Physical Therapy for Acute Lateral Epicondylitis

Phase 4

Completed

Conditions: Tennis Elbow
Epicondylitis, Lateral Humeral

Interventions: Drug: Placebo
Drug: triamcinolone
Drug: Lidocaine
Other: Physiotherapy
Drug: Naproxen

First Posted Date: 2009-01-22

Last Posted Date: 2022-01-24

Lead Sponsor: University of Oslo

Target Recruit Count: 177

Registration Number: NCT00826462

Locations: 🇳🇴
Grålum legesenter, Sarpsborg, Norway

A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects

Phase 4

Completed

Conditions: Arthritis, Juvenile Rheumatoid

Interventions: Drug: Celecoxib
Drug: Naproxen

First Posted Date: 2008-12-12

Last Posted Date: 2021-02-02

Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Target Recruit Count: 201

Registration Number: NCT00807846

Locations: 🇺🇸
University of Nebraska Medical Center Pediatric Research Office, Omaha, Nebraska, United States
🇨🇱
Hospital Roberto del Rio, Santiago, RM, Chile
🇷🇸
Institute of Rheumatology, Belgrade, Serbia

and more 36 locations

Efficacy of Flavocoxid 500 mg Compared With Naproxen 500 mg in Subjects With Moderate-severe Osteoarthritis of the Knee

Not Applicable

Completed

Conditions: Osteoarthritis of Knee

Interventions: Dietary Supplement: flavocoxid
Drug: Naproxen

First Posted Date: 2008-11-14

Last Posted Date: 2022-11-01

Lead Sponsor: Primus Pharmaceuticals

Target Recruit Count: 223

Registration Number: NCT00790985

A Randomized Controlled Trial of Oral Naproxen and Transdermal Estradiol for Bleeding in LNG-IUC

Not Applicable

Completed

Conditions: Bleeding
Contraception

Interventions: Drug: transdermal estradiol
Drug: oral placebo
Drug: naproxen

First Posted Date: 2008-11-13

Last Posted Date: 2018-03-20

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 129

Registration Number: NCT00789802

Locations: 🇺🇸
Washington University School fo Medicine, Saint Louis, Missouri, United States

Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition

Phase 1

Terminated

Conditions: Healthy Volunteers

Interventions: Drug: CG100649 (2 mg)
Drug: CG100649 (8 mg)
Drug: Celecoxib
Drug: Acetazolamide
Drug: Placebo capsules
Drug: Naproxen

First Posted Date: 2008-10-27

Last Posted Date: 2014-02-06

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 26

Registration Number: NCT00780325

Locations: 🇺🇸
Institute for Translational Medicine and Therapeutics (ITMAT), University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States